A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation.

Trial Profile

A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs ICT 107 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors ImmunoCellular Therapeutics
  • Most Recent Events

    • 21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release.
    • 21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated immune monitoring data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
    • 22 Aug 2016 According to an ImmunoCellular Therapeutics media release, the company plans to present immune monitoring data from this trial at the Society for NeuroOncology Annual Scientific Meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top